DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...
The "Protein Engineering for Pharmaceutical Biotechnology Training Course (Jan 21st - Jan 22nd, 2026)" training has been added to ResearchAndMarkets.com's offering. Enhance your knowledge in protein ...
AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.
China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.
The "Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of all ...
Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical ...
North Carolina, ranked in the top five states for life sciences by Business Facilities, is home to a thriving ecosystem specializing in bio and pharmaceutical manufacturing. Propelled by a low cost of ...
Hosted on MSN
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) stands ...
Feb 4 (Reuters) - Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development. The ...
Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Identify research insights to guide ...
During the first six months of this year, the pharmaceutical-biotech industry completed construction on a total of 31 new plants and research centers across North America During the first six months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results